Propofol phosphate

Drug Profile

Propofol phosphate

Alternative Names: Neuprox™; Propofol prodrug

Latest Information Update: 30 May 2011

Price : $50

At a glance

  • Originator Vyrex Corporation
  • Class General anaesthetics; Phenols; Small molecules
  • Mechanism of Action GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Anaesthesia; Migraine; Neurological disorders; Parkinson's disease

Most Recent Events

  • 31 Aug 2008 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
  • 31 Aug 2008 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)
  • 31 Aug 2008 Discontinued - Preclinical for Migraine in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top